Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Please amend claims 4, 7 to 15, 17, 18, 20, and 21 as follows:

1. (original): A method of producing a colloidal preparation comprising cationic colloidal nanoparticles and an active agent comprising the steps of

a) providing an active agent,

b) providing empty cationic nanoparticles comprising a cationic component and

c) incubating said active agent of step a) with the empty cationic colloidal nanoparticles of step b) in an aqueous medium for a period of time sufficient to cause loading of said agent into said cationic nanoparticles,

wherein step c) is performed without further steps as a self-assembly process.

2. (original): The method of claim 1, wherein said active agent is water soluble and/or comprises an anionic moiety and a moiety which can interact by amphiphilic interactions and wherein said active agent has a high partition coefficient into said nanoparticles in an aqueous solution.

3. (currently amended): The method of claim 1 [~~claims 1 or 2~~], wherein said active agent is present in an amount of about 0.1 mol% to less than about 100 mol%, preferably from about 1 mol% to about 50 mol%, more preferably from about 3 mol% to about 30 mol% and most preferably from about 5 mol% to about 10 mol% with respect to the amount of said cationic component of said cationic nanoparticles of step b).

4. (currently amended): The method of [~~any one of claims 1 to 3~~] claim 1, wherein said active agent is selected from a camptothecin drug in the carboxylate form.

5. (original): The method of claim 4, wherein said camptothecin drug is selected from camptothecin, 10-OH-CPT or SN38.

6. (original): The method of claims 4 or 5, wherein the lactone form of a camptothecin drug is present in said preparation in an amount of below about 10%, preferably of below about 8%, more preferably of below about 6% and more preferably of below about 4% with respect to the total amount of the carboxylate drug.

7. (currently amended): The method of [~~any one of the claims 4 to 6~~] claim 4, wherein said camptothecin drug can be present as an aqueous solution or a solid product.

8. (currently amended): The method of [~~any one of claims 1 to 7~~] claim 1, wherein said cationic nanoparticles of step b) are selected from micelles, liposomes and nanocapsules.

9. (currently amended): The method of [~~any one of the claims 1 to 8~~] claim 1, wherein said empty cationic nanoparticles of step b) can be present as an aqueous dispersion or a solid product.

10. (currently amended): The method of [~~any one of claims 1 to 9~~] claim 1, wherein said cationic nanoparticles of step b) comprise as cationic component cationic amphiphiles or polymers, particularly cationic polyelectrolytes.

11. (currently amended): The method of [~~any one of the claims 1 to 10~~] claim 1, wherein said cationic nanoparticles of step b) comprise as cationic component cationic lipids, particularly cationic lipids selected from DOTAP or DMTAP.

12. (currently amended): The method of [~~any one of the claims 1 to 11~~] claim 1, wherein said incubation time of step c) is between about 10 min and about 6 hours, preferably between about 30 min and about 2 hours.

13. (currently amended): The method of [~~any one of the claims 1 to 12~~] claim 1, wherein said incubation temperature of step c) is between about 4°C and about 25°C, preferably about 25°C.

14. (currently amended): The method of [~~any one of claims 1 to 13~~] claim 1, wherein said preparation is obtained after c) and which is suitable for immediately, e. g. directly administering it to a subject in need thereof.

15. (currently amended): The method of [~~any one of the claims 1 to 14~~] claim 1, wherein said colloidal preparation has a pH in the range of about 6 to about 8.

16. (canceled)

17. (currently amended): A pharmaceutical composition comprising a colloidal preparation produced by a method of [~~any one of claims 1 to 15~~] claim 1, optionally together with a pharmaceutically acceptable carrier, diluent and/or adjuvant.

18. (currently amended): A kit ~~Kit~~ comprising a) an active agent, b) empty cationic nanoparticles and optionally c) an aqueous medium, wherein said active agent is water soluble and/or comprises an anionic moiety and a moiety which can interact by amphiphilic interactions and wherein said active agent has a high partition coefficient into said nanoparticles in an aqueous solution, wherein the components a), b) and optionally c) are in separate containers.

19. (original): The kit of claim 18, wherein said active agent is a camptothecin drug in the carboxylate form.

20. (currently amended): The kit of claim 18 [~~claims 18 or 19~~] for the manufacture of a pharmaceutical composition.

21. (currently amended): The kit of [~~anyone of claims 18 to 20~~] claim 18 for the manufacture of a medicament for an angiogenesis associated disease such as cancer.

22. (new): A method of treating an angiogenesis associated disease comprising administering an effective amount of the composition of claim 17 to a patient in need thereof.